Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

by Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, Benoit Callendret
Published 2016-05-01

A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.

by Robert T Cartee, Ann Thanawastien, Thomas J Griffin Iv, John J Mekalanos, Stephan Bart, Kevin P Killeen
Published 2020-01-01

Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

by Sybil Tasker, Anna Wight O’Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart, Vyjayanthi Krishnan, Jianfeng Zhang, Katie J. Anderson, Bertrand Georges, M. Scot Roberts
Published 2021-03-01